American Tech Today
SEE OTHER BRANDS

Hottest science and technology news from the United States

American Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.

Press releases published on May 13, 2025

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 …

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results

Continued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent Portfolio Expanded to Support Pipeline …

Reviva to Participate in the A.G.P. Healthcare Company Showcase

Reviva to Participate in the A.G.P. Healthcare Company Showcase

CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central …

Advanced Technology International Acquires Carrot

Advanced Technology International Acquires Carrot

SUMMERVILLE, S.C., May 13, 2025 (GLOBE NEWSWIRE) -- We are excited to announce that effective March 31, 2025, Advanced Technology International (ATI), a South Carolina based 501(c)3 public service nonprofit, acquired the assets of The Common Pool, LLC, dba …

red violet to Present at the 25th Annual B. Riley Securities Investor Conference

red violet to Present at the 25th Annual B. Riley Securities Investor Conference

BOCA RATON, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced that it will present at the 25th Annual B. Riley Securities Investor Conference being held May 21-22 …

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend …

Reflect Scientific Secures Patents for Data Center Cooling with Cryogenic Innovation

Reflect Scientific Secures Patents for Data Center Cooling with Cryogenic Innovation

OREM, Utah, May 13, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leader in cryogenic technology, today announced a U.S. Patent for its innovative system to cool computer rooms using cryogenic methods. This development addresses the …

Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™

Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™

The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second …

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) …

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …

Acronis Ecosystem Reaches 300 Technology Integrations, Drives New Opportunities for MSPs and ISVs

Acronis Ecosystem Reaches 300 Technology Integrations, Drives New Opportunities for MSPs and ISVs

SHAFFHAUSEN, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- Acronis, a global leader in cybersecurity and data protection, today announces a significant milestone in the Acronis Technology Ecosystem, which now includes nearly 300 integrations, reinforcing …

NEVGOLD ADDS MORE SIGNIFICANT OXIDE GOLD-ANTIMONY RESULTS:  2.19 G/T AUEQ OVER 64.0 METERS (0.72 G/T AU AND 0.33% ANTIMONY), INCLUDING 4.17 G/T AUEQ OVER 24.1 METERS (1.47 G/T AU AND 0.60% ANTIMONY), AND ALSO INCLUDING 10.86 G/T AUEQ OVER 4.50 METERS…

NEVGOLD ADDS MORE SIGNIFICANT OXIDE GOLD-ANTIMONY RESULTS: 2.19 G/T AUEQ OVER 64.0 METERS (0.72 G/T AU AND 0.33% ANTIMONY), INCLUDING 4.17 G/T AUEQ OVER 24.1 METERS (1.47 G/T AU AND 0.60% ANTIMONY), AND ALSO INCLUDING 10.86 G/T AUEQ OVER 4.50 METERS…

Vancouver, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that it has discovered further significant oxide gold-antimony (“Antimony”, “Sb”) …

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and …

Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies

Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies

In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs) In 15% or …

Intuitive Machines Reports First Quarter 2025 Financial Results

Intuitive Machines Reports First Quarter 2025 Financial Results

HOUSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), a leading space technology and infrastructure services company, today announced its financial results for the first quarter ended …

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“ …

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agreement – - …

Atomic Minerals Announces Share Exchange Agreement to Acquire Quebec Mineral Claims

Atomic Minerals Announces Share Exchange Agreement to Acquire Quebec Mineral Claims

Vancouver, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Atomic Minerals Corporation ("Atomic Minerals" or the "Company") (TSX Venture: ATOM) is pleased to announce that it has entered into a share exchange agreement (the “Agreement”) with the …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service